Skip to content

Cash ratio at other companies

Stryker logo
StrykerSYK
0.5×+0.2×
Vericel logo
VericelVCEL
2.3×+0.3×
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
0.1×-0.5×
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
1.3×+0.4×
Bioventus logo
BioventusBVS
0.2×+0.1×
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
0.6×+0.5×

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's cash ratio?
Anika Therapeutics (ANIK) reported cash ratio of 2× in Q1 2026.
How has Anika Therapeutics's cash ratio changed year-over-year?
Anika Therapeutics's cash ratio decreased by 34.4% year-over-year, from 3× to 2×.
What is the long-term trend for Anika Therapeutics's cash ratio?
Over 5 years (2020 to 2025), Anika Therapeutics's cash ratio has grown at a 0.2% compound annual growth rate (CAGR), from 2.6× to 2.6×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.